Trial · NCT04975269
Acetazolamide Trial in Normal Pressure Hydrocephalus
NCT04975269, Phase 2, Completed, Uppsala University Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Acetazolamide Trial in Normal Pressure Hydrocephalus. Trials, record NCT04975269. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04975269
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Acetazolamide Trial in Normal Pressure Hydrocephalus
- NCT number
- NCT04975269
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 50 participants, actual
- Lead sponsor
- Uppsala University Hospital
- Conditions
- Idiopathic Normal Pressure Hydrocephalus (INPH)
- Interventions
- Acetazolamide, Placebo
- First posted
- 2021-07-23
- Last updated
- 2026-05-06
Source ClinicalTrials.gov
Registered outcomes13
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Proportional change in gait function | Change from baseline gait function immediately after intervention (at time of shunt surgery) | Gait function is determined by one variable that is calculated as the mean time and number of steps of three different gait tests: 10 meter walking in self chosen speed, timed up and go test (TUG) and 3 m walking backwards. The two fastest attempts of three attempts for each test are documented. The mean time and number of steps of the two fastest attempts for the three tests are calculated to a single variable and the proportional difference between study visits is used as the primary outcome variable. |
| Secondary | Change in idiopathic normal pressure hydrocephalus (iNPH) scale | Change from baseline iNPH-scale score immediately after intervention (at time of shunt surgery) | Swedish idiopathic normal pressure hydrocephalus (iNPH) scale that is a combination of subscales for gait, balance, cognition and continence. Minimum value is 0 and maximum value is 100. High values indicate better function. |
| Secondary | Change in volume of periventricular hyperintensities | Change from baseline at 3 months | Measured using volumetric MRI |
| Secondary | Change in cerebral blood perfusion | Change from baseline at 3 months | Measured using pseudo continuous arterial spin labeling (MRI perfusion) |
| Secondary | Change in quantified CSF flow in cerebral aqueduct | Change from baseline at 3 months | Measured using phase contrast MRI |
| Secondary | Change in parenchymal water content | Change from baseline at 3 months | Measured using Synthetic MRI |
| Secondary | Change in cerebral myelin volume | Change from baseline at 3 months | Measured using Synthetic MRI |
| Secondary | Changes in plasma biomarkers | Change from baseline immediately after intervention (at time of shunt surgery) | Change in plasma levels of neurofilament light chain protein, Total-tau, amyloid beta-42, glial fibrillary acidic protein will be measured using Quanterix (SIMOA). |
| Secondary | Change in CSF biomarkers | Change from baseline immediately after intervention (at time of shunt surgery) | CSF levels of neurofilament light chain protein, Total-tau, amyloid beta-42, glial fibrillary acidic protein will be measured using Quanterix (SIMOA). |
| Secondary | Changes in plasma and CSF proteins | Change from baseline immediately after intervention (at time of shunt surgery) | Semi-quantified levels of approximately 200 proteins are measured with proximity extension assay (Neurology panel and Neuro exploratory panel, Olink.com). |
1 to 10 of 13Source ClinicalTrials.gov
See all 13 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers7
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04975269
GET https://conductscience.org/api/trials/v1/NCT04975269/registered